公开(公告)号：US20200345732A1

公开(公告)日：2020-11-05

申请号：US16934787

申请日：2020-07-21

Applicant: Novartis AG

Inventor： Atwood Kim CHEUNG ,  Donovan Noel CHIN ,  Natalie DALES ,  Aleem FAZAL ,  Timothy Brian HURLEY ,  John KERRIGAN ,  Gary O'BRIEN ,  Lei SHU ,  Robert SUN ,  Moo Je SUNG

IPC: A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  C07D237/20 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  A61K31/41 ,  A61K31/427 ,  C07D237/06

Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20170290828A1

公开(公告)日：2017-10-12

申请号：US15364248

申请日：2016-11-29

Applicant: NOVARTIS AG

Inventor： Atwood Kim CHEUNG ,  Donovan Noel CHIN ,  Natalie DALES ,  Aleem FAZAL ,  Timothy HURLEY ,  John KERRIGAN ,  Gary O'BRIEN ,  Lei SHU ,  Robert SUN ,  Moo Je SUNG

IPC: A61K31/501 ,  A61K31/41 ,  C07D237/06 ,  C07D413/14 ,  C07D405/14 ,  C07D403/10 ,  C07D403/12 ,  A61K31/427 ,  C07D401/14

CPC classification number: A61K31/501 ,  A61K31/41 ,  A61K31/427 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  C07D237/06 ,  C07D237/20 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10

Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20250026736A1

公开(公告)日：2025-01-23

申请号：US18823254

申请日：2024-09-03

Applicant: NOVARTIS AG

Inventor： Simone BONAZZI ,  Artiom CERNIJENKO ,  Jennifer Stroka COBB ,  Janetta DEWHURST ,  John Ryan KERRIGAN ,  Gary O'BRIEN ,  MooJe SUNG ,  Noel Marie-France THOMSEN ,  Pamela TING

IPC: C07D401/14 ,  A61K31/4545 ,  A61K31/55 ,  A61K45/06 ,  C07D405/14

Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

公开(公告)号：US20220402904A1

公开(公告)日：2022-12-22

申请号：US17124127

申请日：2020-12-16

Applicant: NOVARTIS AG

Inventor： Simone BONAZZI ,  Artiom CERNIJENKO ,  Jennifer Stroka COBB ,  Natalie DALES ,  John Ryan KERRIGAN ,  Philip LAM ,  Hasnain Ahmed MALIK ,  Gary O'BRIEN ,  Andrew W. PATTERSON ,  Noel Marie-France THOMSEN ,  Pamela TING

IPC: C07D413/14 ,  C07D401/14 ,  C07D471/04 ,  C07D417/14 ,  A61K45/06

Abstract: The present disclosure relates to compounds of formula (I′) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

公开(公告)号：US20240158374A1

公开(公告)日：2024-05-16

申请号：US18460428

申请日：2023-09-01

Applicant: Novartis AG

Inventor： Simone BONAZZI ,  Artiom CERNIJENKO ,  Jennifer Stroka COBB ,  Natalie Alysia DALES ,  Janetta DEWHURST ,  Matthew James HESSE ,  Rama JAIN ,  John Ryan KERRIGAN ,  Hasnain Ahmed MALIK ,  James R. MANNING ,  Gary O'BRIEN ,  Andrew W. PATTERSON ,  Noel Marie-France THOMSEN ,  Pamela YF TING

IPC: C07D403/14 ,  A61P7/00 ,  C07D405/14 ,  C07D417/14

CPC classification number: C07D403/14 ,  A61P7/00 ,  C07D405/14 ,  C07D417/14

Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

公开(公告)号：US20220387428A1

公开(公告)日：2022-12-08

申请号：US17644045

申请日：2021-12-13

Applicant: Novartis AG

Inventor： Atwood Kim CHEUNG ,  Donovan Noel CHIN ,  Natalie DALES ,  Aleem FAZAL ,  Timothy Brian HURLEY ,  John KERRIGAN ,  Gary O'BRIEN ,  Lei SHU ,  Robert SUN ,  Moo Je SUNG

IPC: A61K31/501 ,  A61P21/00 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  C07D237/20 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  A61K31/41 ,  A61K31/427 ,  C07D237/06

Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20220363671A1

公开(公告)日：2022-11-17

申请号：US17642292

申请日：2020-09-16

Applicant: NOVARTIS AG

Inventor： Jake AXFORD ,  Rohan Eric John BECKWITH ,  Simone BONAZZI ,  Nicole BUSCHMANN ,  Artiom CERNIJENKO ,  Janetta DEWHURST ,  Aleem FAZAL ,  Matthew James HESSE ,  Lauren HOLDER ,  Viktor HORNAK ,  Hidetomo IMASE ,  Rama JAIN ,  Xianming JIN ,  John Ryan KERRIGAN ,  Julie LACHAL ,  Fupeng MA ,  Hasnain Ahmed MALIK ,  James R. MANNING ,  Daniel MCKAY ,  Robert Joseph MOREAU ,  Pierre NIMSGERN ,  Gary O'BRIEN ,  Anna VULPETTI ,  Ken YAMADA ,  Junping ZHAO

IPC: C07D405/04 ,  A61K31/513 ,  C07D471/04 ,  C07D413/04 ,  C07D401/14

Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.

公开(公告)号：US20190358226A1

公开(公告)日：2019-11-28

申请号：US16237907

申请日：2019-01-02

Applicant: Novartis AG

Inventor： Atwood Kim CHEUNG ,  Donovan Noel CHIN ,  Natalie DALES ,  Aleem FAZAL ,  Timothy Brian HURLEY ,  John KERRIGAN ,  Gary O'BRIEN ,  Lei SHU ,  Robert SUN ,  Moo Je SUNG

IPC: A61K31/501 ,  A61K31/427 ,  C07D487/10 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  C07D237/06 ,  C07D487/04 ,  A61K45/06 ,  C07D237/20 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  A61K31/41

Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.